Actividad Investigadora
Estudio de investigación que compara en qué medida reducen la glucemia diferentes dosis del medicamento NNC0487-0111 en personas con diabetes tipo 2.
Datos básicos
Objetivos del proyecto
This phase 2 study is designed to investigate the safety, efficacy and PK properties of QW s.c. and QD oral NNC0487-0111 in participants with T2D inadequately controlled (HbA1c 7.0-10.0 %) on a stable dose of metformin with or without an SGLT2 inhibitor. The primary objective is to determine and characterise the dose-response relationship of s.c. and oral NNC0487-0111 on change in HbA1c from baseline to week 36 in participants with T2D.
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
NOVO NORDISK, S.A.
